- Home
- CGEM vs DGICB Comparison
CGEM vs DGICB Comparison
Compare CGEM & DGICB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEM
- DGICB
- Stock Information
- Founded
- CGEM 2016
- DGICB 1986
- Country
- CGEM United States
- DGICB United States
- Employees
- CGEM N/A
- DGICB N/A
- Industry
- CGEM Biotechnology: Pharmaceutical Preparations
- DGICB Property-Casualty Insurers
- Sector
- CGEM Health Care
- DGICB Finance
- Exchange
- CGEM Nasdaq
- DGICB Nasdaq
- Market Cap
- CGEM 530.0M
- DGICB 599.2M
- IPO Year
- CGEM 2021
- DGICB N/A
- Fundamental
- Price
- CGEM $7.81
- DGICB $18.50
- Analyst Decision
- CGEM Strong Buy
- DGICB
- Analyst Count
- CGEM 5
- DGICB 0
- Target Price
- CGEM $30.00
- DGICB N/A
- AVG Volume (30 Days)
- CGEM 371.7K
- DGICB 3.3K
- Earning Date
- CGEM 08-07-2025
- DGICB 07-24-2025
- Dividend Yield
- CGEM N/A
- DGICB 3.51%
- EPS Growth
- CGEM N/A
- DGICB 1206.68
- EPS
- CGEM N/A
- DGICB 2.03
- Revenue
- CGEM N/A
- DGICB $993,637,805.00
- Revenue This Year
- CGEM N/A
- DGICB $3.27
- Revenue Next Year
- CGEM N/A
- DGICB $4.01
- P/E Ratio
- CGEM N/A
- DGICB $10.15
- Revenue Growth
- CGEM N/A
- DGICB 5.29
- 52 Week Low
- CGEM $6.85
- DGICB $10.75
- 52 Week High
- CGEM $21.01
- DGICB $20.46
- Technical
- Relative Strength Index (RSI)
- CGEM 41.43
- DGICB 50.79
- Support Level
- CGEM $7.53
- DGICB $17.61
- Resistance Level
- CGEM $9.25
- DGICB $20.46
- Average True Range (ATR)
- CGEM 0.38
- DGICB 0.58
- MACD
- CGEM -0.13
- DGICB 0.03
- Stochastic Oscillator
- CGEM 13.02
- DGICB 33.73
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
About DGICB Donegal Group Inc. Class B
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.